NCT04447651: Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: SF3B1,U2AF1, SRSF2
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have genomic testing on a tumor that shows a spliceosome mutation (SF3B1, U2AF1 or SRSF2)

Up ↑